Jessica Guarnaschelli
Independent Consultant CURADH Pharmaceuticals
Seminars
Wednesday 22nd July 2026
Scientific Advisory Board Fireside Chat: Radiopharmaceuticals in 2026- Landscape Signals, Inflection Points & What Comes Next?
8:30 am
Step inside a candid, forward-looking conversation with the field’s scientific leaders as they dissect what the data has – and hasn’t – told us about radiopharmaceuticals heading into 2026. Challenge
assumptions, explore inflection points, and put your questions directly to the experts shaping the next wave of innovation, regulation, and clinical design
- Which scientific assumptions about radiopharmaceutical behavior have held up under clinical data through 2026 – and which are now clearly incomplete or wrong?
- Are current pharmacokinetic and dosimetry models sufficiently predictive for decision-making, or are we still over-relying on empirical iteration in the clinic?
- What is needed in the field to continue investment and movement?
- What lessons from recent late-stage programs should be influencing how we design first-in-human studies today?
- Does existing regulatory paradigms adequately reflect the unique risk–benefit calculus of radiopharmaceuticals, or is misalignment now a rate-limiting step?
- Which manufacturing and supply-chain constraints are a fundamentally scientific problem – and which require more infrastructural changes?
- Looking ahead, what scientific bottleneck is most likely to determine winners and failures in radiopharmaceuticals beyond 2026?
Tuesday 21st July 2026
Roundtable Discussion – Designing the Ideal Radioligand Therapy by Integrating Isotope, Chelator, & Targeting Moiety Selection
11:30 am
Pull up a chair for this high-energy collaborative session where you will join your industry peers to dissect the “Holy Trinity” of RLT design and solve complex integration puzzles. It’s time to trade insights, challenge traditional selection criteria, and then share your group’s top 3 thoughts and discussion points back to the room!
- Bringing together preclinical and early clinical perspectives to explore how to optimize RLT design for efficacy, safety, and translational readiness
- Balancing isotope properties, emission type, and half-life with clinical objectives
- Selecting chelation strategies to ensure stability, delivery, and safety
- Matching targeting moieties to tumor biology and therapeutic goals
Thursday 23rd July 2026
Panel Discussion: Personalized VS Non- Personalized Dosimetry in Widespread RLT Treatment – Necessary or Unsustainable?
2:30 pm
- Comparing personalized versus standard dosimetry approaches and their impact on patient safety and treatment efficacy
- Assessing operational, logistical, and cost challenges of implementing individualized dosimetry at scale
- Evaluating strategies to balance precision treatment with practical feasibility in widespread RLT adoption
Thursday 23rd July 2026
Managing Toxicity & Therapeutic Index in Radioligand Therapy Clinical Development to Improve Patient Outcomes Whilst Retaining Efficacy
